Literature DB >> 30577044

Muscle-Specific Kinase Autoimmune Myasthenia Gravis: Report of a Pediatric Case and Literature Review.

Thouraya Ben Younes1, Hanene Benrhouma1,2, Hedia Klaa1,2, Rania Ben Aoun1,2, Aida Rouissi1,2, Melika Ben Ahmed2,3, Ichraf Kraoua1,2, Ilhem Ben Youssef-Turki1,2.   

Abstract

Myasthenia gravis (MG) with antibodies to the muscle-specific tyrosine kinase (MuSK-MG) receptor is a rare entity. It represents 5 to 8% of all MG patients. Few pediatric cases were reported. Clinical presentation is often atypical. It is characterized by predominant involvement of cranial, bulbar, and axial muscles and early respiratory crises. Myokymia and fasciculation are suggestive of MuSK-MG. The clinical course of patients with MuSK-MG is worse than other types of MG. Responses to standard therapies are variable. We report clinical, neurophysiological, serological, and outcome profile of a Tunisian child with MuSK-MG. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Year:  2018        PMID: 30577044     DOI: 10.1055/s-0038-1676514

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  3 in total

1.  Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature.

Authors:  XiuShan Ge; CuiJie Wei; Hui Dong; YueHua Zhang; XinHua Bao; Ye Wu; DanYu Song; HongJun Hao; Hui Xiong
Journal:  Front Pediatr       Date:  2022-05-11       Impact factor: 3.569

2.  Long-Term Efficacy of Non-steroid Immunosuppressive Agents in Anti-Muscle-Specific Kinase Positive Myasthenia Gravis Patients: A Prospective Study.

Authors:  Ying Tan; Jiayu Shi; Yangyu Huang; Ke Li; Jingwen Yan; Li Zhu; Yuzhou Guan; Liying Cui
Journal:  Front Neurol       Date:  2022-06-13       Impact factor: 4.086

3.  Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility.

Authors:  Hui Deng; Jianjian Wang; Xiaotong Kong; Huixue Zhang; Tianfeng Wang; Wenqi Tian; Tingting Yi; Lihua Wang
Journal:  BMC Med Genet       Date:  2019-10-30       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.